

NIPER Raebareli Signs MoU, CDA, and Technology Transfer Agreement with Lofty Laboratories

Academia-Industry Partnership to Promote Indigenous Technology Commercialization in Biotechnology Sector

Posted On: 08 MAY 2026 3:20PM by PIB Delhi



National Institute of Pharmaceutical Education and Research (NIPER), Raebareli has signed a **Memorandum of Understanding (MoU), Confidential Disclosure Agreement (CDA), and Technology Transfer Agreement** with **Lofty Laboratories, Hyderabad** to foster multidirectional collaboration in research, innovation, and technology commercialization.

This MoU marks a significant step towards **strengthening academia-industry** partnerships aimed at **advancing pharmaceutical and biotechnology research**. During the signing ceremony, both the organizations agreed to adopt an industry-ready technology developed at NIPER-Raebareli for further commercialization and development. The collaboration will also include joint participation in research and development activities in areas of mutual interest.

Speaking during the occasion, the Director of NIPER-Raebareli, Prof. Shubhini A. Saraf, stated that the MoU and technology transfer agreement would enable both institutions to complement each other's research programs in multiple ways, including collaborative participation in the activities of the **Institute's Center of Excellence on Novel Drug Delivery Systems (CoE-NDDS)**.

Prof. Saraf also highlighted the importance of the technology developed in CoE and expressed hope that several more technologies from the Institute would be ready for transfer by the end of the year.

Addressing the gathering, Prof. Nihar Ranjan, Head, CoE-NDDS explained that commercialization of the present technology would significantly reduce the cost of gel-staining agents, which are extensively used worldwide in biology-related research, particularly in studies involving genes, cancer, and other nucleic acid-related diseases. He added that indigenous production of such novel gel-staining agents would contribute substantially towards strengthening India's pharmaceutical and biotechnology sectors.

PC/PM

(Release ID: 2259032) Visitor Counter : 292

Read this release in: Urdu , हिन्दी , Tamil